Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
Spero Therapeutics (SPRO) Stock Price & Analysis
422 Followers
SPRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.68 - $3.18
Previous Close$1.82
Volume181.59K
Average Volume (3M)558.50K
Market Cap
$95.68M
Enterprise Value$5.89M
Total Cash (Recent Filing)$96.25M
Total Debt (Recent Filing)$6.47M
Price to Earnings (P/E)-2.0
Beta0.63
Next Earnings
Aug 10, 2023EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding52,571,813
10 Day Avg. Volume246,331
30 Day Avg. Volume558,503
Standard Deviation0.29
R-Squared0.03
Alpha0.00060
Financial Highlights & Ratios
Price to Book (P/B)1.67
Price to Sales (P/S)46.24
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.12
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$6.00Price Target Upside238.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Spero Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $0.68 and its highest was $3.18 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Currently, no data Available
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Aug 10, 2023 which is in 66 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on May 11, 2023. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.083.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc does not currently pay dividends.
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -$0.39.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 52,571,810 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went down -3.646%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in SPRO
---
Spero Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (238.98% Upside)
$6.00 (238.98% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.00%
12-Months-Change
Fundamentals
Return on Equity
-42.18%
Trailing 12-Months
Asset Growth
-22.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding SPRO
Vanguard Total Stock Market ETF
$1.58M
iShares Core S&P Total U.S. Stock Market ETF
$65.11K
Up to five ETFs with an Outperform Smart Score that hold SPRO. The ETFs are listed according to market value of SPRO within the ETF
---
---